Antifungal prophylaxis in neutropenia

Current Opinion in Infectious Diseases

Volumn 12, Issue 6, 1999, Pages 549-555

  Maertens, Johan A ^a   Boogaerts, Marc A ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOLYTE; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; FLUCONAZOLE; PYRROLE DERIVATIVE;

ALLOGENIC BONE MARROW TRANSPLANTATION; EARLY DIAGNOSIS; HUMAN; LUNG ASPERGILLOSIS; MORBIDITY; MORTALITY; MYCOSIS; NEUTROPENIA; PROPHYLAXIS; REVIEW;

EID: 0033373601     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199912000-00004     Document Type: Review

References (49)

1. 1 Guiot HFL, Fibbe WE, van't Wout JW. Risk factors for fungal infection in patients with malignant hematologic disorders: implications for empirical therapy and prophylaxis. Clin Infect Dis 1994; 18:525-532.
2. 2 Boogaerts MA. Anti-infective strategies in neutropenia. J Antimicrob Chemother 1995; 36:167-178.
3. 3 Dismukes WE. Established and emerging invasive mycoses. Infect Dis Clin Pract 1998; 7 (Suppl 1).S35-41.
4. 4 Groll AH, Shah OM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996; 33:23-32.
5. 5 Bodey G, Bueltmann B, Duguid W, Gibbs D, Hanak H, Hotchi M, et al. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis 1992; 11:99-109.
6. 6 Denning DW, Marinus A, Cohen J, Spence D, Herbrecht R, Pagano L, et al. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. J Infect 1998; 37:173-180.
7. 7 Maertens J, Verhaegen J, Demuynck H, Brock P, Verhoef G, Van Eldere J, et al. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich-enzyme linked immunosorbent assay for hematological patients at risk for invasive aspergillosis. J Clin Microbiol: 1999; 37:3223-3228. This article assesses the value of a commercially available noninvasive diagnostic tool in high-risk patients for invasive aspergillosis by using stringent diagnostic criteria.
8. 8 Einsele H, Hebart H, Roller G, Löffler J, Rothenhöffer C, Müller C, et al. Detection and identification of fungal pathogens in blood by using molecular probes. J Clin Microbiol 1997; 35:1353-1360.
9. 9 Heussel CP, Kauczor HU, Heussel GE, Fischer B, Begrich M, Mildenberger P, et al. Pneumonia in febrile neutropenic patients and in bone marrow and blood stem-cell transplant recipients: use of high-resolution computed tomography. J Clin Oncol 1999; 17:796-805. A large German study examines the role of high resolution computed tomography for early detection of pneumonia in febrile neutropenic patients with unknown focus of infection.
10. 10 Boogaerts MA. Antifungal prophylaxis in neutropenic patients. Int J Antimicrob Agents 1996; 6:149-154.
11. 11 Pittet D, Mourouga P, Perneger TV. Compliance with handwashing in a teaching hospital. Ann Intern Med 1999; 130:126-130. The poor compliance of hand washing among nurses and physicians is described in this paper.
12. 12 De Pauw BE. Practical modalities for prevention of fungal infections in cancer patients. Eur J Clin Microbiol Infect Dis 1997; 16:32-41.
13. 13 Schwartz S, Behre G, Heinemann V, Wandt H, Schilling E, Arning M, et al. Aerosolized amphotericin B inhalations as prophylaxis of invasive Aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood 1999; 11:3654-3661. First prospective randomized trial that demonstrates the lack of efficacy of aerosolized amphotericin B in the prevention of invasive aspergillosis in neutropenic patients.
14. 14 Conneally E, Cafferkey MT, Daly PA, Keane CT, McCann SR. Nebulized amphotericin B as prophylaxis against invasive aspergillosis in granulocytopenic patients. Bone Marrow Transplant 1990; 5:403-406.
15. 15 Erjavec Z, Woolthuis GMH, de Vries-Hospers HG, Sluiter WJ, Daenen SMGJ, de Pauw B, et al. Tolerance and efficacy of amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in haematological patients. Eur J Clin Microbiol Infect Dis 1997; 16:364-368.
16. 16 Cicogna CE, White MH, Bernard EM, Ishimura T, Sun M, Tong WP, et al. Efficacy of prophylactic aerosol amphotericin B lipid complex in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother 1997; 41:259-261.
17. 17 Allen SD, Sorensen KN, Nejdl MJ, Durrant C, Proffit RT. Prophylactic efficacy of aerosolized liposomal (Ambisome) and non-liposomal (Fungizone) amphotericin B in murine pulmonary aspergillosis. J. Antimicrob Chemother 1994; 34:1001-1013.
18. 18 Lambros MP, Bourne DWA, Abbas SA, Johnson DL. Disposition of aerosolized liposomal amphotericin B. J Pharmaceutical Sciences 1997; 86:1066-1069.
19. 19 Rousey SR, Russler S, Gottlieb M, Ash RC. Low-dose amphotericin B prophylaxis against invasive Aspergitlus infections in allogeneic marrow transplantation. Am J Med 1991; 91:484-492.
20. 20 O'Donnell MR, Schmidt GM, Tegtmeier BR, Faucett C, Fahey JL, Ito J, et al. Prediction of systemic fungal infection in allogeneic marrow recipients: impact of amphotericin prophylaxis in high-risk patients. J Clin Oncol 1994; 12:827-834.
21. 21 Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing marrow transplantation. J Infect Dis 1997; 175:1459-1466.
22. 22 Perfect JR, Klotman ME, Gilbert CC, Crawford DD, Rosner GL, Wright KA, et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 1992; 165:891-897.
23. 23 Riley DK, Pavia AT, Beatty PG, Petersen FB, Spruance JL, Stokes R, et al. The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. Am J Med 1994; 97:509-514.
24. 24 Bodey GP, Anaissie EJ, Elting LS, Estey E, Obrien S, Kantarjian H. Antifungal prophylaxis during remission induction therapy for acute leukemia: fluconazole versus intravenous amphotericin B. Cancer 1994; 73:2099-2106.
25. 25 Tollemar J, Ringdén O, Andersson S, Sundberg B, Ljungman P, Tydén G. Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1993; 12:577-582.
26. 26 Kelsey SM, Goldman JM, McCann S, Newland AC, Scarffe JH, Oppenheim BA, et al. Liposomal amphotericin B (Ambisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study. Bone Marrow Transplant 1999; 23:163-168.
27. 27 Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. New Engl J Med 1992; 326:841-851.
28. 28 Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study. J Infect Dis 1995; 171:1545-1552.
29. 29 Winston DW, Chandrasekar PH, Lazarus HM, Goodman JL, Silber JL, Horowitz H, et al. Fluconazole prophylaxis of fungal infection in patients with acute leukemia. Results of a randomized placebo-controlled, double blind, multicenter trial. Ann Intern Med 1993; 118:495-503.
30. 30 Menichetti F, Del Favero A, Martino P, Bucaneve G, Micozzi A, D'Antonio D, et al. Preventing fungal infections in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. Ann Intern Med 1994; 120:913-918.
31. 31 Kern W, Behre G, Rudlof T, Kerkhoff A, Grote-Metke A, Eimermacher H, et al. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory myeloid leukaemia. Cancer 1998; 83:291-301. Prospective randomized study that examines the prophylactic efficacy of fluconazole in this very high-risk patient population.
32. 32 Rotstein C, Bow EJ, Laverdiere M, Ioannou S, Carr D, Moghaddam N, et al. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. Clin Infect Dis 1999; 28:331-340. This study identified subgroups of leukaemic patients that might benefit from fluconazole prophylaxis.
33. 33 Thunnissen PLM, Sizoo W, Hendriks WDH. Safety and efficacy of itraconazole in prevention of fungal infections in neutropenic patients. Neth J Med 1991; 39:84-91.
34. 34 Prentice AG, Bradford GR. Prophylaxis of fungal infections with itraconazole during remission-induction therapy. Mycoses 1989; 32 (Suppl 1):96-102.
35. 35 Lamy T, Bernard M, Courtois A, Jacquelinet C, Chevrier S, Dauriac C, et al. Prophylactic use of itraconazole for the prevention of invasive pulmonary aspergillosis in high risk neutropenic patients. Leuk Lymphoma 1998; 30:163-174.
36. 36 Böhme A, Just-Nübling G, Bergmann L, Shah PM, Stille W, Hoelzer D. Itraconazole for prophylaxis of systemic mycoses in neutropenic patients with haematological malignancies. J Antimicrob Chemother 1996; 38:953-961.
37. 37 Glasmacher A, Molitor E, Hahn C, Bomba K, Ewig S, Leutner C, et al. Antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia. Leukemia 1998; 12:1338-1343.
38. 38 Tricot G, Joosten E, Boogaerts MA, Vande Pitte J, Cauwenbergh G. Ketoconazole versus itraconazole or antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies. Rev Infect Dis 1987; 9 (Suppl 1):S94-S99.
39. 39 Vreugdenhil G, Van Dijke BJ, Donnelly JP, Novakova IRO, Raemaekers JMM, Hoogkamp-Korstanje MAA, et al. Leuk Lymphoma 1993; 11:353-358.
40. 40 Huijgens PC, Simoons-Smit AM, van Loenen AC, Prooy E, van Tinteren, Ossenkoppele GJ, Jonkhoff AR. Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology. J Clin Pathol 1999; 52:375-380. A nice randomized trial comparing low doses of currently available triazoles in chemoprophylaxis.
41. 41 Summers KK, Hardin TC, Gore SJ, Graybill JR. Therapeutic drug monitoring of systemic anti-fungal therapy. J Antimicrob Chemother 1997; 40:753-764.
42. 42 Menichetti F, Del Favero A, Martino P, Bucaneve G, Micozzi A, Girmenia C, et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. Clin Infect Dis 1999; 28:250-255. Pivotal study evaluating the efficacy of a new formulation of itraconazole with increased bioavailability in a placebo-controlled setting.
43. 43 Morgenstern GR, Prentice AG, Prentice HG, Ropner JE, Schey SA, Wamock DW. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. Br J Haematol 1999; 105:901-911. This paper examines the role of two azole suspensions in the prevention of invasive fungal infections.
44. 44 Harousseau J-L, Stamatoullas A, Dekker A, De Bock B, Bassaris H, Fassas A, et al. Prophylaxis of fungal infections in haematological malignancy: a double-blind trial comparing itraconazole oral solution to amphotericin B capsules [abstract J-101] in: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 1998.
45. 45 Albengres E, Le Louet H, Tillement JP. Systemic antifungal agents: drug interactions of clinical significance. Drug Saf 1998; 18:83-97. A comprehensive overview of clinically important drug interactions and combinations in antifungal therapy.
46. 46 Todeschini G, Murari C, Bonesi R, Pizzolo G, Amaddi G, Ambrosetti A, et al. Oral itraconazole plus nasal amphotericin B for prophylaxis of invasive aspergillosis in patients with hematological malignancies. Eur J Clin Microbiol Infect Dis 1993; 12:614-618.
47. 47 De Pauw BE, Meis JFGM. Progress in fighting systemic fungal infections in haematological neoplasia. Support Care Cancer 1998; 6:31-38. A critical review of the evidence based practice in antifungal prophylaxis in patients with hematological disorders.
48. 48 Wingard JR. Early intervention in invasive fungal disease with antifungal drugs. Infect Dis Clin Pract 1998; 7 (Suppl 1):S49-S56.
49. 49 Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses study group. N Engl J Med 1999; 340:764-771. A large study describing once more that liposomal amphotericin B is as effective as conventional amphotericin B, but with less infusion-related and compound-related toxicity.